Latest Pharmaceutical Development of Imeglimin Electrospinning Nanofibers for Diabetic Treatment-Reference-Cited by-同舟云学术

Latest Pharmaceutical Development of Imeglimin Electrospinning Nanofibers for Diabetic Treatment

Published:2024-05-18 Issue:1 Volume:5 Page:5-8
ISSN:
Container-title:Diabetes Research: Open Access
language:en
Short-container-title:Diab Res Open Access

Author:

Bando Hiroshi¹^ORCID,Ogawa Hiroko²,Bando Masahiro³

Affiliation:

1. Shikoku Division of Integrative Medicine Japan (IMJ), Tokushima, Japan; Medical Research/Tokushima University, Tokushima, Japan; Shuseikai Medical Corporation, Yoshinogawa Hospital, Tokushima, Japan

2. Shuseikai Medical Corporation, Yoshinogawa Hospital, Tokushima, Japan

3. Shikoku Division of Integrative Medicine Japan (IMJ), Tokushima, Japan

Abstract

Among oral hypoglycemic agents (OHAs), imeglimin (Twymeeg) has been evaluated in clinical practice with Trials of Imeglimin for Efficacy and Safety (TIMES) 1-3 international studies. However, its gastrointestinal adverse effect (GIAE) would be an actual problem. Recently, imeglimin electrospinning nanofibers have been reported as a potential buccal antidiabetic therapeutic approach, which shows absorption not via the gastrointestinal (GI) tract. Imeglimin nanofibers have a diameter of 361 ± 54 nm and a drug-loading (DL) of 23.5 ± 0.2 μg/mg of fibers. The solid nanofibers disintegration takes only 2 ± 1 seconds. This novel medicine is expected to lead to optimal therapeutic outcomes with better patient compliance.

Publisher

Asploro Open Access Publications

Reference18 articles.

1. Hossain MJ, Al-Mamun M, Islam MR. Diabetes mellitus, the fastest growing global public health concern: Early detection should be focused. Health Sci Rep. 2024 Mar 22;7(3):e2004. [PMID: 38524769]

2. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1):S158-78. Erratum in: Diabetes Care. 2024 May 02. [PMID: 38078590]

3. Bando H, Yamashita H, Kato Y, Ogura K, Kato Y. Combined Treatment of Vildagliptin/Metformin (Equmet) and Imeglimin (Twymeeg) with Clinical Efficacy. Asp Biomed Clin Case Rep. 2023 Apr 14;6(2):69-75.

4. Singh AK, Singh A, Singh R, Misra A. Efficacy and safety of imeglimin in type 2 diabetes: A systematic review and meta-analysis of randomized placebo-controlled trials. Diabetes Metab Syndr. 2023 Feb;17(2):102710. [PMID: 36702046]

5. Reilhac C, Dubourg J, Thang C, Grouin JM, Fouqueray P, Watada H. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period. Diabetes Obes Metab. 2022 May;24(5):838-48. [PMID: 34984815]